Annexin Pharmaceuticals AB

As of June 30, 2026, Annexin Pharmaceuticals AB TEMP has 7.43M shares outstanding.

As of June 30, 2026, Annexin Pharmaceuticals AB TEMP maintains a current ratio of 1.19, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Annexin Pharmaceuticals AB TEMP posted a negative return on equity (ROE) of -177.51, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -148.86, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 4.00, a quick read on workforce productivity versus industry peers.

As of the close on July 15, 2026, Annexin Pharmaceuticals AB TEMP's stock has gained approximately 3657.58% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Annexin Pharmaceuticals AB TEMP generated - - in revenue and converted that into -42.49M in net income, yielding earnings per share of -5.87. EBITDA reached -42.91M, while operating income came in at -43.18M.

As of June 30, 2026, Annexin Pharmaceuticals AB TEMP holds 5.27M in cash and equivalents against - - in total debt, resulting in a net debt position of -5.27M. Total book value stands at 2.52M, with working capital of 1.03M providing operational flexibility.

Annexin Pharmaceuticals AB TEMP produced -40.52M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -129,000.00 in capital expenditures, free cash flow totaled -40.65M - equivalent to -5.62 per share.